Samsung Bioepis Co., Ltd. announced today new data supporting consistent efficacy of SB16 (OBODENCE®1), a biosimilar to Prolia2 (denosumab) across patient subgroups compared to the reference denosumab. The data will be presented as a poster presentation at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO) 2026 in Prague from April 16 to 19. “Consistent efficacy across patient subgroups is critical in reinforcing physician confidence and advancing tr

Storm Therapeutics has closed a $56 million series C financing as the British biotech kicks off a phase 2 sarcoma trial of its RNA-modifying enzyme inhibitor. Proceeds from the financing will support the mid-stage study of a METTL3 inhibitor dubbed STC-15, which is designed to reprogram malignant progenitor cells by modulating mRNA methylation, according to an April 16 release. The trial, for which the first patient has now been dosed, will assess STC-15 as a monotherapy in various sarcoma indi

Rapid Medical™, a leading developer of active endovascular devices, today announced U.S. FDA clearance of the TIGERTRIEVER™ 25, the latest addition to its TIGERTRIEVER platform, along with the first clinical cases demonstrating its performance in treating large vessel occlusion (LVO) stroke. Designed specifically for large clot burden in proximal vessels, TIGERTRIEVER 25 combines a 53 mm capture length with proprietary real-time force control. This capability, unique to the TIGERTRIEVER platform

April 13, 2026 -- Veld Pharmaceuticals GmbH (“Veld”), a Switzerland-based pharmaceutical access and services company, today announced a collaboration with Chiesi Farmaceutici S.p.A (“Chiesi”) to expand patient access to nine rare-disease therapies through a Managed Access Program (MAP) across Africa. The program is designed to enable physicians, where permitted by local regulations, to prescribe these therapies to patients with serious unmet medical needs who meet defined medical eligibility

AbbVie presented Phase II results for mirvetuximab soravtansine (Elahere) in folate receptor alpha (FRα)-positive, recurrent platinum-sensitive ovarian cancer at the SGO 2026 Annual Meeting. The open-label IMGN853-0420 trial reported a confirmed objective response rate of 62.7% (95% CI, 52.6–72.1) in the primary FRα ≥50% subgroup after six cycles of combination induction therapy, the company said. The 125-patient trial enrolled adults with FRα-positive recurrent platinum-sensitive high-grade ep

April 13, 2026 -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the first participants have been dosed in a Phase 1 clinical trial of AKB-9090, an internally developed hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor being evaluated for the treatment of cardiac surgery-associated acute kidney injury (AKI). The Phase 1 randomized, double-blind, placebo-controlled, sing

Phase 1/2 RAINFOL™-01 data showed the combination of rinatabart sesutecan (Rina-S®) and bevacizumab was tolerable, with no new safety signals in patients with advanced ovarian cancer The ongoing Phase 3 RAINFOL-04 trial will further evaluate the combination in patients with recurrent platinum-sensitive ovarian cancer (PSOC) Genmab A/S (Nasdaq: GMAB) announced today new data demonstrating that rinatabart sesutecan (Rina-S®), an investigational folate receptor alpha (FRα)-targeted, topoisomerase

April 13, 2026 -- Kazia Therapeutics Limited (Nasdaq: KZIA), a clinical-stage oncology company advancing therapies to reprogram cancer biology and overcome treatment resistance, announces the in-licensing of a first-in-class SETDB1-targeted epigenetic drug development platform from QIMR Berghofer. The platform includes use of an AI-integrated epigenetic drug discovery engine, enabling rapid, precise, and scalable candidate generation. The lead drug candidate, MSETC, was discovered and optimized

Novel TBL1 targeting strategy drives nuclear β-catenin degradation, inhibits oncogenic transcription, and demonstrates potent anti-tumor activity in complex solid tumors The company continues to build clinical momentum in hepatocellular carcinoma while expanding development into colorectal cancer, as well as other Wnt-driven cancers April 13, 2026 -- Iterion Therapeutics announced that two abstracts featuring its first-in-class TBL1 inhibitor, tegavivint, will be presented at the 2026 American

BioOra and Cincinnati Children's unite to evaluate Atla-cel in paediatric relapsed or refractory B-ALL, building on emerging adult clinical data demonstrating markedly reduced neurotoxicity with this next-generation CAR-T therapy. BioOra and Cincinnati Children's are partnering to advance Atla-cel, a paediatric CAR‑T therapy for relapsed/refractory B‑ALL. Atla‑cel shows markedly reduced neurotoxicity in adult trials, supporting its evaluation in children who could benefit from this therapy not